Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > ORGANIZATION
ORGANIZATION
- Keizai Doyukai Urges Government to Switch All Long-Listed Products to Generics to Cut Social Security Costs
March 29, 2013
- Survey by Japan Hospital Association Finds Big Increase in Accounts Receivable per Hospital in 2012
March 27, 2013
- FPMAJ to Set Up International Affairs Committee and Self-Medication Task Force
March 25, 2013
- JPMA Suspends Activities of Vice President Hasegawa for Six Months and Membership of Nihon Pharmaceutical
March 22, 2013
- JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
March 22, 2013
- JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
- EFPIA Simulation: New Drug Market Up Mere 0.4 Trillion Yen by 2022 Even with Premium
March 19, 2013
- Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
- Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
- JPMA Issues Statement Calling for IP Protection, Expresses Concerns over Issuance of Compulsory Licenses
March 7, 2013
- Generic Market Share at 26.1% on Volume Basis in 3rd Quarter FY2012: JGA
March 6, 2013
- Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
- Yakukeiren’s Direct Joint Purchasing System for Generic Drugs to Go into Full Operation in FY2013
February 27, 2013
- TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
- JPMA’s Nakatani Says Transparency Guidelines Will Go into Force in April as Planned
February 25, 2013
- JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
- Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
- Pharmaceutical Trade Deficit “Not Directly Related to Global Competitiveness” of Domestic Industry: Mr Nagasawa of OPIR
February 20, 2013
- JMA to Host WMA Expert Conference on Revision of Helsinki Declaration in Tokyo on Feb. 28
February 20, 2013
- Biotech Association Asks MHLW to Include Drugs for Intractable Diseases and Orphan Drugs in Early Approval System
February 18, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…